Tianeptine: Opioid Activity, Dependence, Withdrawal, and U.S. Safety Evidence

Executive summary

Tianeptine is an atypical antidepressant used medically in some countries, but it is not approved by the U.S. Food and Drug Administration for any medical use. In the United States it has nevertheless been sold through some convenience stores, smoke or vape shops, online sellers, and products marketed as supplements or “nootropics.” FDA has repeatedly warned consumers not to use these products because of serious adverse events and dependence risk [1,2].

The key pharmacology is no longer mysterious: tianeptine is a mu-opioid receptor (MOR) agonist. A 2014 receptor study identified direct MOR agonism and much weaker delta-opioid receptor activity [4]. That finding helps explain why high or repeated exposures can produce opioid-like intoxication, tolerance, physical dependence, and withdrawal.

Human evidence is strongest for safety risk, not therapeutic benefit. U.S. poison-center surveillance documented increasing exposure calls, including cases with neurologic, cardiovascular, gastrointestinal, and respiratory effects as well as withdrawal [3]. More recent case reports and case series describe severe dependence and opioid-like withdrawal [6-8].

What remains weak is the evidence for a standardized treatment protocol specific to tianeptine. Published reports describe use of medications commonly used for opioid use disorder, particularly buprenorphine-containing treatment, but the literature is still dominated by case reports and small case series rather than controlled trials [6-8]. That is enough to justify medical evaluation; it is not enough to turn one case report into a self-treatment recipe.

Bottom line: tianeptine should not be treated as a benign supplement, a safe “research chemical,” or a proven self-directed treatment for depression, pain, anxiety, or opioid use disorder in the United States.

What is tianeptine?

Tianeptine is a prescription antidepressant in parts of Europe, Asia, and Latin America. It has historically been described as an “atypical tricyclic” because its clinical history does not fit neatly into the standard SSRI/SNRI story.

That history can create confusion in U.S. discussions. A compound can have a legitimate prescription role in one regulatory system while still being unapproved, illegally marketed, or unsafe in unregulated consumer products elsewhere. FDA states that tianeptine is not approved for any U.S. medical use and has warned against products sold with claims involving mood, cognition, pain, and opioid use disorder [1,2].

The evidence also needs to distinguish pharmaceutical tianeptine used under medical regulation from unregulated U.S. products. Product identity, concentration, co-ingredients, contaminants, and labeling accuracy can all change the real-world risk.

Why tianeptine is relevant to opioid pharmacology

The most important mechanistic study was published in 2014. Gassaway and colleagues found that tianeptine is an efficacious agonist at the human mu-opioid receptor, with substantially weaker activity at the delta-opioid receptor and no meaningful kappa-opioid receptor activity in the assays reported [4].

That matters because MOR is the principal receptor through which many opioids produce analgesia, reward, sedation, respiratory depression, tolerance, and physical dependence. It does not mean every MOR agonist produces identical risk at every exposure. Real-world outcomes depend on potency, dose, metabolism, brain exposure, duration, co-exposures, and individual vulnerability.

Preclinical work adds another caution. A 2023 mouse study found MOR-dependent analgesic, locomotor, and rewarding effects and reported tolerance after chronic exposure under the tested conditions [5]. Animal findings cannot establish the incidence of human addiction, but they strengthen the biological plausibility of the tolerance and dependence signals seen in clinical reports.

What U.S. safety data show

CDC analyzed tianeptine exposure calls reported to U.S. poison control centers from 2000 through 2017. Calls increased markedly in the later years of that period. Reported effects included neurologic, cardiovascular, and gastrointestinal symptoms, with some cases resembling opioid toxicity. Withdrawal-associated calls were also documented [3].

FDA now describes a broader and more current safety concern. Its consumer information notes increasing U.S. reports of severe adverse effects and warns that tianeptine products are not FDA-approved. FDA safety communications have described seizures, loss of consciousness, hospitalization, and deaths reported after use of some marketed tianeptine products [1,2].

These surveillance systems do not tell us the precise probability of harm for an individual user. Poison-center and adverse-event reports are subject to underreporting, reporting bias, uncertain product composition, and frequent co-exposures. They are best interpreted as signals that serious harm is occurring, not as a denominator-based incidence estimate.

Dependence and withdrawal: what is actually documented?

Human reports make it clear that tianeptine can be associated with tolerance, escalating use, physical dependence, and a clinically significant withdrawal syndrome. Symptoms described across poison-center data and case reports overlap substantially with opioid withdrawal, including agitation, gastrointestinal distress, autonomic symptoms, anxiety, and severe subjective discomfort [3,6-8].

A useful distinction is:

• Physical dependence means the body has adapted to repeated exposure and withdrawal can occur when exposure falls or stops.
• Tolerance means a given effect may require greater exposure over time.
• Substance use disorder includes behavioral features such as impaired control, compulsive use, functional harm, and continued use despite consequences.

These concepts overlap but are not interchangeable. A person can be physically dependent without meeting criteria for a substance use disorder, and a receptor assay by itself proves neither.

A 2026 report describing three cases and reviewing the literature emphasized rapid tolerance, severe withdrawal, opioid-like intoxication, and the need for clinical treatment pathways [8]. The value of that paper is not that three cases define everyone’s course; it is that the pattern is now repeatedly recognizable across independent clinical reports.

Is tianeptine withdrawal an opioid withdrawal syndrome?

Clinically, the overlap can be substantial because tianeptine engages MOR. CDC noted withdrawal effects that resembled opioid withdrawal [3], and published case reports have described management using medications ordinarily used in opioid-use-disorder care [6-8].

But “resembles opioid withdrawal” should not be simplified into “every tianeptine withdrawal case should be managed exactly like heroin or fentanyl withdrawal.” Tianeptine has additional pharmacology, product exposures vary, psychiatric comorbidity may be important, and co-use of other substances is common in published reports.

That is why this page does not provide a home detox schedule or medication-dosing instructions. The evidence supports medical assessment and individualized treatment, especially when use is heavy, withdrawal is severe, there are co-exposures, pregnancy is involved, or mental-health symptoms are unstable.

What evidence exists for treatment?

Published case reports describe successful treatment with buprenorphine/naloxone in some people with tianeptine dependence [6,7]. A 2026 case series and literature review likewise argues that medications used for opioid use disorder can be clinically relevant because of the opioid-like intoxication and withdrawal pattern [8].

The major limitation is study design. Case reports can show that an approach was feasible in a particular patient; they cannot establish an optimal induction strategy, comparative effectiveness, relapse rate, or a universal protocol. Controlled tianeptine-specific treatment trials remain lacking.

So the evidence hierarchy should be kept explicit:

1. Strong mechanistic evidence: tianeptine activates MOR [4].
2. Meaningful human safety evidence: poison-center surveillance and FDA adverse-event signals document real toxicity and withdrawal [1-3].
3. Repeated clinical dependence evidence: case reports and small case series describe tolerance, withdrawal, and use-disorder patterns [6-8].
4. Limited treatment evidence: medications used for opioid use disorder have been used successfully in reported cases, but controlled tianeptine-specific trials are absent [6-8].

Pregnancy and neonatal withdrawal

Pregnancy is a particularly high-risk context. A 2024 case report described neonatal opioid withdrawal after chronic prenatal exposure to a tianeptine-containing product, with the infant’s presentation resembling opioid withdrawal [9]. A single case cannot quantify risk, but it reinforces that unregulated tianeptine exposure during pregnancy should not be treated as equivalent to an ordinary dietary supplement.

Product quality is part of the risk

With unregulated psychoactive products, pharmacology is only one layer of uncertainty. The label may not fully describe:

• the actual tianeptine concentration;
• other active ingredients;
• contaminants or adulterants;
• batch-to-batch variability;
• whether the marketed chemical identity matches the contents.

FDA has specifically warned that some marketed products may contain harmful ingredients not listed on the label [2]. That uncertainty makes online dose comparisons and anecdotal “safe use” thresholds especially unreliable.

What tianeptine is not proven to do

Current U.S. evidence does not establish unregulated tianeptine products as safe or effective treatments for:

• depression or anxiety in the U.S. consumer-product context;
• chronic pain;
• opioid withdrawal;
• opioid use disorder;
• cognitive enhancement;
• self-directed detoxification.

Foreign prescription use should not be used as a shortcut around the absence of U.S. approval, product regulation, or controlled evidence for retail products.

When urgent evaluation matters

Seek urgent medical help for severe sedation, trouble breathing, loss of consciousness, seizures, chest pain, severe confusion, or rapidly worsening symptoms after tianeptine or an unknown psychoactive product. If dependence or withdrawal is the concern, a clinician experienced in addiction medicine, emergency medicine, or medical toxicology can evaluate severity, co-exposures, psychiatric risk, and appropriate treatment.

In the United States, Poison Control can provide case-specific toxicology guidance at 1-800-222-1222. This is particularly useful when the product identity or ingredients are uncertain.

Related evidence

• Substance Use, Dependence & Harm Reduction hub
• Mitragynine evidence review
• 7-Hydroxymitragynine evidence review
• MGM-15 / dihydro-7-hydroxymitragynine
• Mitragynine pseudoindoxyl
• Corynoxine B opioid and addiction evidence review
• Kratom & 7-OH withdrawal evidence
• Novel psychoactive substances

Evidence gaps worth watching

The highest-value unanswered questions are not more receptor assays. They are:

• prospective human pharmacokinetics across real-world products;
• denominator-based estimates of dependence and overdose risk;
• the contribution of contaminants and co-ingredients to severe events;
• validated clinical criteria for tianeptine withdrawal severity;
• controlled comparisons of treatment approaches;
• longer-term outcomes after treatment for tianeptine use disorder;
• pregnancy and neonatal safety data beyond individual case reports.

Until those questions are answered, the safest scientific position is neither “tianeptine is just an antidepressant” nor “tianeptine is exactly the same as every other opioid.” It is a MOR-active drug with documented human toxicity, dependence, and withdrawal signals, sold in a U.S. market where product quality and medical oversight can be poor.